Palliative Radiation Therapy for Treatment of Cutaneous T-cell Lymphoma in a Double Yellow-headed Amazon Parrot (Amazona oratrix).

A 17-year-old captive female double yellow-headed Amazon parrot (Amazona oratrix) was presented to the Kansas State University Zoological Medicine Service (Manhattan, KS, USA) for a 2-month history of a left sided facial swelling. On examination, a red, raised mass was noted on the left side of the face. A whole-body computed tomography scan of the bird was performed to assess the extent of the mass and evaluate the patient for obvious evidence of disseminated disease. No systemic involvement was detected, and the swelling was localized to the cutaneous and subcutaneous tissues overlying the left rhamphotheca. Two punch biopsies were collected, and histopathology was consistent with cutaneous lymphoma, with strong positive CD3 staining congruous with a T-cell origin. Because of a lack of evidence for disseminated disease, the authors elected to pursue localized radiation therapy, and a single fraction of 8 Gray was administered. The swelling had resolved by the time of the recheck examination 4 weeks post-radiation therapy, and the patient remained clinically normal 52 weeks after radiation therapy.

High-concentration buprenorphine exceeds target plasma concentrations for extended periods following subcutaneous administration in American flamingos (Phoenicopterus ruber).

OBJECTIVE: To determine the pharmacokinetic parameters of a high-concentration buprenorphine formulation after a single SC dose in American flamingos (Phoenicopterus ruber). ANIMALS: 6 healthy adult American flamingos (3 males and 3 females). METHODS: A single dose of high-concentration buprenorphine (1.8 mg/kg) was administered SC to all birds. Blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours after drug administration between October 14 and October 18, 2022. Plasma buprenorphine concentrations were determined by liquid chromatography-tandem mass spectrometry and a noncompartmental analysis was used to determine pharmacokinetic parameters. RESULTS: Mean ± SD peak plasma drug concentration (Cmax) was 195.1 ± 187.4 ng/mL, the mean time to peak plasma concentration (Tmax) was 0.32 ± 0.31 hours, the mean area under the concentration-vs-time curve from time 0 to the last measured concentration (AUC0-last) was 881.4 ± 205.4 ng/mL, and mean terminal half-life (t1/2) was 12.6 ± 3.86 hours. Mean plasma buprenorphine concentrations were >1 ng/mL for at least 48 hours after drug administration. No clinically significant adverse effects were observed. CLINICAL RELEVANCE: High-concentration buprenorphine dosed at 1.8 mg/kg SC in American flamingos rapidly exceeded plasma drug concentrations reported to have analgesic effects in other avian species and maintained these levels for extended periods. Sedative effects were similar to those reported for other species. Additional studies are needed to evaluate the clinical efficacy of high-concentration buprenorphine at this dose in American flamingos.

Keratinized Odontogenic Cysts in a Malayan Tiger (Panthera tigris jacksoni).

A 14-year-old male intact Malayan tiger (Panthera tigris jacksoni) was presented for a routine annual wellness exam and comprehensive oral health assessment and treatment, during which an odontogenic cyst was incidentally diagnosed from radiographs. Prior to a second immobilization for computed tomography (CT) and surgical removal of the cyst, the tiger developed anorexia, lethargy, and reluctance to train, which were clinical signs suspected to be reflective of pain secondary to the odontogenic cyst. A CT scan of the skull revealed 2 odontogenic cyst lesions associated with teeth 204-207 and 208-209, and associated tooth root resorption, focal lysis of the maxilla, communication with the left nasal passage, thinning of the ventral margin of the left orbit and maxillary foramen, and left mandibular lymphadenopathy. Complete enucleation of each cyst wall and surgical extraction of associated teeth were performed. Histopathologic findings were consistent with an odontogenic cyst containing keratinized stratified squamous epithelium, keratin debris within the cyst lumen, and a lymphoplasmacytic inflammatory infiltrate. Postoperatively, the tiger recovered uneventfully, clinical signs resolved within 2 weeks and have not recurred at the time of publication of this article. Similar keratinized odontogenic cysts are described in dogs, and there is only one other case report in a felid. This is the first known report of an odontogenic cyst in a tiger and of a keratinized odontogenic cyst in a nondomestic species.

Point of Care Ultrasound in Exotic Animal Emergency and Critical Care.

Exotic pets are presented to veterinary clinics with increasing frequency for routine, urgent, and emergency needs. With these increased visits, owners' expectations for high-quality veterinary care are also increasing. Many presenting complaints of reptiles, birds, and small mammals can benefit from the use of point of care ultrasound (POCUS) to establish a minimum database, aid in triage, and help guide further diagnostics, treatment, and prognostic discussions with the owner. Hospitalized exotic patients can also have their progress tracked and better assessed with the aid of POCUS.

Retrospective evaluation of wobbly hedgehog syndrome in 49 African pygmy hedgehogs (Atelerix albiventris): 2000-2020.

OBJECTIVE: To retrospectively evaluate the prevalence and clinical progression of wobbly hedgehog syndrome (WHS) and concurrent incidence of neoplasia in a cohort of African pygmy hedgehogs (Atelerix albiventris). ANIMALS: 49 hedgehogs. CLINICAL PRESENTATION AND PROCEDURES: Medical records of hedgehogs from 7 institutions across the US over a 20-year period (2000 to 2020) were retrospectively reviewed. Inclusion criteria were hedgehogs of any sex or age with postmortem CNS histopathology consistent with WHS. Collected data included sex, age at onset and euthanasia, major histopathologic findings, reported neurologic clinical signs, and treatments administered. RESULTS: 24 males and 25 females were included. Fifteen of 49 (31%) individuals had subclinical WHS with no reported antemortem neurologic clinical signs. In neurologically affected (clinical) hedgehogs (n = 34), the mean ± SD age at onset was 3.3 ± 1.5 years with a median (range) time from onset to euthanasia of 51 days (1 to 319 days). In neurologically affected hedgehogs, the most commonly reported clinical signs were ataxia (n = 21) and pelvic limb paresis (16) and the most commonly administered treatment was meloxicam (13). Overall, 31 of 49 (63%) hedgehogs had a concurrent histopathologic diagnosis of neoplasia outside of the CNS. CLINICAL RELEVANCE: The prognosis for hedgehogs with WHS is poor. No treatment had a significant effect on survival time, and neoplasia was a common comorbidity in the current cohort. A small but clinically relevant subset of neurologically normal hedgehogs had a histopathologic diagnosis of WHS.

Diagnosis and management of a peripheral T-cell lymphoproliferative disease in an American pine marten (Martes americana).

A 9-year-old neutered male American pine marten (Martes americana) was referred for further evaluation of suspected lymphoproliferative disease. On physical examination, the pine marten was determined to be in an underconditioned state with an enlarged right mandibular lymph node. Hematology revealed a marked leukocytosis characterized by a lymphocytosis. Flow cytometry performed on peripheral blood was suggestive of a CD4+ T-cell lymphoproliferative disease. Whole-body radiographs demonstrated a large cranial mediastinal mass and splenomegaly. These findings were confirmed using ultrasound, which also identified intra-abdominal lymphadenopathy and splenic nodules. Cytologic evaluation of aspirates from the mediastinal mass was interpreted as possible lymphoma. The pine marten was treated with chlorambucil and prednisolone and achieved a durable partial remission. Twelve months after initial diagnosis, progressive disease was noted and treatment with lomustine was initiated as a rescue protocol until euthanasia, which was carried out 15 mo after the initial diagnosis. Based on a literature search, this is the first case report describing the management of peripheral T-cell lymphoproliferative disease, presumably peripheral lymphoma, in a pine marten; this neoplasm should be considered as a differential diagnosis in pine martens that have abnormal complete blood cell count findings and enlarged lymph nodes. Key clinical message: This report describes the diagnosis and management of a peripheral T-cell lymphoproliferative disease, presumably peripheral lymphoma, in an American pine marten (Martes americana). This is the first report of this disease and its successful treatment in a pine marten.

Diagnostic et prise en charge d'une maladie lymphoproliférative à cellules T périphériques chez une martre d'Amérique ( Martes americana ). Une martre d'Amérique (Martes americana) mâle castré âgé de 9 ans a été référée pour une évaluation plus approfondie d'une suspicion de maladie lymphoproliférative. À l'examen physique, il a été déterminé que la martre était dans un état sous-optimal avec un ganglion lymphatique mandibulaire droit élargi. L'hématologie a révélé une hyperleucocytose marquée caractérisée par une lymphocytose. La cytométrie en flux réalisée sur le sang périphérique était évocatrice d'une maladie lymphoproliférative des lymphocytes T CD4+. Les radiographies du corps entier ont montré une importante masse médiastinale crânienne et une splénomégalie. Ces résultats ont été confirmés par échographie, qui a également identifié une lymphadénopathie intra-abdominale et des nodules spléniques. L'évaluation cytologique des aspirations de la masse médiastinale a été interprétée comme un possible lymphome. La martre d'Amérique a été traitée avec du chlorambucil et de la prednisolone et une rémission partielle durable a été obtenue. Douze mois après le diagnostic initial, une progression de la maladie a été notée et un traitement par lomustine a été initié comme protocole de sauvetage jusqu'à l'euthanasie, qui a été réalisée 15 mois après le diagnostic initial. Sur la base d'une recherche documentaire, il s'agit du premier rapport de cas décrivant la prise en charge d'une maladie lymphoproliférative périphérique à cellules T, vraisemblablement un lymphome périphérique, chez une martre d'Amérique; ce néoplasme doit être considéré comme un diagnostic différentiel chez les martres d'Amérique qui présentent des résultats anormaux de numération globulaire complète et des ganglions lymphatiques hypertrophiés.Message clinique clé :Ce rapport décrit le diagnostic et la prise en charge d'une maladie lymphoproliférative à cellules T périphériques, vraisemblablement un lymphome périphérique, chez une martre d'Amérique (Martes americana). Il s'agit du premier signalement de cette maladie et de son traitement réussi chez une martre d'Amérique.(Traduit par Dr Serge Messier).

Measurement of Cyclooxygenase Products in Plasma as Markers for Inhibition of Cyclooxygenase Isoforms by Oral Meloxicam in New Zealand White Rabbits (Oryctolagus cuniculus ).

Pain management in rabbits is a challenging task that is complicated by the rabbit's ability to hide signs of distress and the limited pharmacologic data available for this species. Pharmacokinetic data has shown that in rabbits, meloxicam, a nonsteroidal anti-inflammatory NSAID, reaches plasma concentrations that are known to provide analgesia in dogs and cats; these concentrations could theoretically alleviate pain in rabbits. However, the inhibitory effects of meloxicam on cyclooxygenase (COX) isoforms have not been studied in rabbits. In this study, we measured the products of COX-1 and COX-2 after the oral administration of a single 1 mg/kg dose of meloxicam to New Zealand White rabbits (n = 6). Blood samples were collected before drug administration (T0) and then at predetermined time points over 48 h. Plasma prostaglandin E2 (PGE2 ) and thromboxane (TxB2) concentrations were measured as surrogate markers for COX-1 and COX-2, respectively, by using commercial ELISA kits. After meloxicam administration, both TxB2 and PGE2 plasma concentrations fell significantly below baseline, with maximal mean reductions to 80% and 60% of baseline at 8 h, respectively. The reduction in PGE2 concentrations was followed by a significant increase that moved its mean plasma concentrations toward baseline between 8 and 24 h. Adverse effects such as lethargy, inappetence, or changes in fecal production were not observed in any rabbits. In conclusion, meloxicam appeared to significantly inhibit both COX-1 and COX-2 with a time course similar to previously reported meloxicam plasma concentration-time profiles in rabbits. Our data suggest that a dosage of 1 mg/kg given orally could provide analgesia to rabbits, but a more frequent dosing interval than the currently recommended daily dosing may be required to maintain clinical efficacy.

Identification and treatment of Strongyloides cebus in captive ring-tailed lemurs (Lemur catta) in the midwestern United States.

Strongyloides spp. are parasitic enteric nematodes that infect a variety of hosts. While the Strongyloides spp. that affect humans, apes, and Old World primates have been previously identified, this genus has not been as fully investigated in prosimian species such as ring-tailed lemurs (Lemur catta). A high burden (4+) of larvated eggs and larvae were identified in the fecal samples of two captive ring-tailed lemurs during routine intake examination at a zoo in the midwestern United States. Conventional PCR targeting the 18S RNA gene of nematodes was used identified the parasite as Strongyloides cebus. The lemurs were initially treated with 0.2 mg/kg ivermectin orally twice, two weeks apart. Repeat fecal sampling showed persistent, but decreased eggs and larvae from 4+ to 3+. Ivermectin treatment was repeated with the addition of fenbendazole at 50 mg/kg orally once daily for 3 days. No parasite stages were seen on fecal samples one week and six weeks after the last ivermectin indicating successful clearance of the infection.

Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus).

OBJECTIVES: To characterize the pharmacokinetics of a single oral dose (6 mg/kg) of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus) and to characterize any clinicopathologic effects with this medication and dose. ANIMALS: Six healthy, 4-month-old New Zealand White rabbits (3 male, 3 female). PROCEDURES: Before drug administration, clinicopathologic samples were collected for baseline data (CBC, serum biochemical analyses, and urinalysis including urine protein-to-creatinine ratio). All 6 rabbits received a single oral dose (6 mg/kg) of mavacoxib. Clinicopathologic samples were collected at set time intervals to compare with the baseline. Plasma mavacoxib concentrations were determined using liquid chromatography with mass spectrometry, and pharmacokinetic analysis was performed using non-compartmental methods. RESULTS: After a single oral dose, the maximum plasma concentration (Cmax; mean, range) was 854 (713-1040) ng/mL, the time to Cmax (tmax) was 0.36 (0.17-0.50) days, the area under the curve from 0 to the last measured time point (AUC0-last) was 2000 (1765-2307) days*ng/mL, the terminal half-life (t1/2) was 1.63 (1.30-2.26) days, and the terminal rate constant (λz) was 0.42 (0.31-0.53) days. All results for CBCs, serum biochemical analyses, urinalyses, and urine protein-to-creatinine ratios remained within published normal reference intervals. CLINICAL RELEVANCE: This study determined that plasma concentrations reached target levels of 400 ng/mL for 48 hours in 3/6 rabbits at 6 mg/kg PO. In the remaining 3/6 rabbits, the plasma concentrations were 343-389 ng/mL at 48 hours, which is below the target concentration. Further research is needed to make a dosing recommendation, including a pharmacodynamic study and investigating pharmacokinetics at different doses and multiple doses.

Association of plasma metabolites and diagnostic imaging findings with hepatic lipidosis in bearded dragons (Pogona vitticeps) and effects of gemfibrozil therapy.

OBJECTIVES: To evaluate the association between plasma metabolites, biochemical analytes, diagnostic imaging findings, and the histologic diagnosis of hepatic lipidosis in bearded dragons. To assess the effects of gemfibrozil therapy on hepatic lipid accumulation and associated diagnostic tests. ANIMALS: Fourteen bearded dragons (Pogona vitticeps) with varying severity of hepatic lipid accumulation (with and without hepatic lipidosis) were included. PROCEDURES: Animals underwent coelomic ultrasound, computed tomography (CT) scans, and coelioscopic hepatic biopsies. Clinical pathology tests included lipidologic tests, hepatic biomarkers, and mass spectrometry-based metabolomics. Animals were medicated with gemfibrozil 6mg/kg orally once a day for 2 months in a randomized blinded clinical trial prior to repeating previous diagnostic testing. RESULTS: Hounsfield units on CT were negatively associated with increased hepatic vacuolation, while ultrasound and gross evaluation of the liver were not reliable. Beta-hydroxybutyric-acid (BHBA) concentrations were significantly associated with hepatic lipidosis. Metabolomics and lipidomics data found BHBA and succinic acid to be potential biomarkers for diagnosing hepatic lipidosis in bearded dragons. Succinic acid concentrations were significantly lower in the gemfibrozil treatment group. There was a tendency for improvement in the biomarkers and reduced hepatic fat in bearded dragons with hepatic lipidosis when treated with gemfibrozil, though the improvement was not statistically significant. CONCLUSIONS: These findings provide information on the antemortem assessment of hepatic lipidosis in bearded dragons and paves the way for further research in diagnosis and treatment of this disease.

Evaluation of Oral Transmucosal Administration of Pentobarbital for Euthanasia of Conscious Wild Birds.

This prospective study evaluated oral transmucosal pentobarbital sodium at three doses in 110 wild-caught wild birds requiring euthanasia. Birds received transmucosal pentobarbital at five (430 mg/kg), six (516 mg/kg), and seven times (602 mg/kg) the intravenous dose for mammals. Time to first effects and loss of consciousness, presence of pupillary light and corneal reflexes, apnea, and asystole were recorded each minute. When asystole was not achieved at 5 minutes, IV pentobarbital was administered. Combining data for all doses, loss of consciousness occurred at a median (range) of 2 minutes (0-4.75 min), apnea at 3 minutes (0-6 min), and asystole at 4 minutes (0.5-5 min). Loss of consciousness and apnea occurred significantly faster in the 602 mg/kg dose group than in the 430 mg/kg group (p = 0.009, difference of 0.6 ± 0.2 min; p = 0.024, difference of 0.7 ± 0.3 min), respectively. Apnea and asystole were achieved in 80/110 birds within 5 minutes. Oral transmucosal pentobarbital results in rapid loss of consciousness and respiratory arrest and provides a reliable alternative euthanasia method compared to intravenous administration.

Examination of the pharmacokinetics and differential inhibition of cyclooxygenase isoenzymes in New Zealand white rabbits (Oryctolagus cuniculus) by the Non-Steroidal anti-inflammatory Robenacoxib.

Effective rabbit analgesia is challenging, and there are few studies available on the newer COX-2 selective NSAIDs, such as robenacoxib. This study aimed to establish the pharmacokinetics of oral and subcutaneous robenacoxib, describe its inhibitory actions on COX enzymes, and develop dosing, using six healthy New Zealand white rabbits. Pharmacokinetics were determined from plasma concentrations after oral administration of robenacoxib (0.83-0.96 mg/kg) and also after subcutaneous administration (2 mg/kg). The inhibitory actions of robenacoxib were evaluated by measuring plasma concentrations of thromboxane B2 (TBX2 ) and prostaglandin E2 (PGE2 ) as surrogate markers of cyclooxygenase enzyme isoform inhibition. The mean maximum concentration for oral and subcutaneous administration was 0.23 µg/ml and 5.82 µg/ml, respectively. Oral robenacoxib administration did not demonstrate a significant difference between any time point for PGE2 or TBX2 , though subcutaneous administration did for both. There was no significant difference in PGE2 or TBX2 concentrations at any time point when comparing subcutaneous versus oral routes. Although the results support that plasma robenacoxib exceeds the therapeutic levels compared to dogs and cats, there was little significance in the difference in the changes associated with COX-1 and COX-2 inhibition. Further studies are warranted to determine appropriate dosing, safety, and efficacy in rabbits.

Pharmacokinetics and ex vivo pharmacodynamics of oral firocoxib administration in New Zealand White rabbits (Oryctolagus cuniculus).

OBJECTIVE: To examine the pharmacokinetics and ex vivo pharmacodynamics of oral firocoxib administration in New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS: 6 healthy New Zealand White rabbits. PROCEDURES: Pharmacokinetics were determined from plasma concentrations measured via ultra performance liquid chromatography-tandem mass spectrometry after oral administration of firocoxib at a dose of 3.74 to 4.20 mg/kg. Pharmacokinetic analysis was performed using non compartmental methods. Pharmacodynamics of firocoxib were evaluated by measuring plasma concentrations of thromboxane and prostaglandin via ELISAs as surrogate markers of cyclooxygenase enzyme isoform inhibition. RESULTS: The terminal rate constant was 0.07 hours (range, 0.05 to 0.11 h). The mean maximum concentration (Cmax) and time to Cmax were 0.16 µg/mL and 3.81 hours (range, 2.0 to 8.0 h), respectively. Mean residence time was 15.02 hours. Mean elimination half-life was 9.12 hours. For the pharmacodynamic analysis, firocoxib administration did not demonstrate a significant difference between any time point for prostaglandin E2 and only a significant difference between 24 and 48 hours for thromboxane B2. CLINICAL RELEVANCE: Although the pharmacokinetic research supports that plasma firocoxib concentrations that would be therapeutic in dogs are achieved in rabbits, the pharmacodynamic results do not demonstrate a significant difference in levels of cyclooxygenase-2 inhibition, which indirectly reflects the anti-inflammatory effects of the drug. Further pharmacodynamic studies and multidose studies are warranted to determine the efficacy and safety of this drug in rabbits.

Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus).

OBJECTIVE: To determine the pharmacokinetics of a solution containing cannabidiol (CBD) and cannabidiolic acid (CBDA), administered orally in 2 single-dose studies (with and without food), in the domestic rabbit (Oryctolagus cuniculus). ANIMALS: 6 healthy New Zealand White rabbits. PROCEDURES: In phase 1, 6 rabbits were administered 15 mg/kg CBD with 16.4 mg/kg CBDA orally in hemp oil. In phase 2, 6 rabbits were administered the same dose orally in hemp oil followed by a food slurry. Blood samples were collected for 24 hours to determine the pharmacokinetics of CBD and CBDA. Quantification of plasma CBD and CBDA concentrations was determined using a validated liquid chromatography-mass spectrometry (LC-MS) assay. Pharmacokinetics were determined using noncompartmental analysis. RESULTS: For CBD, the area under the curve extrapolated to infinity (AUC)0-∞ was 179.8 and 102 hours X ng/mL, the maximum plasma concentration (Cmax) was 30.4 and 15 ng/mL, the time to Cmax (tmax) was 3.78 and 3.25 hours, and the terminal half-life (t1/2λ) was 7.12 and 3.8 hours in phase 1 and phase 2, respectively. For CBDA, the AUC0-∞ was 12,286 and 6,176 hours X ng/mL, Cmax was 2,573 and 1,196 ng/mL, tmax was 1.07 and 1.12 hours, and t1/2λ was 3.26 and 3.49 hours in phase 1 and phase 2, respectively. Adverse effects were not observed in any rabbit. CLINICAL RELEVANCE: CBD and CBDA reached a greater Cmax and had a longer t1/2λ in phase 1 (without food) compared with phase 2 (with food). CBDA reached a greater Cmax but had a shorter t1/2λ than CBD both in phase 1 and phase 2. These data may be useful in determining appropriate dosing of cannabinoids in the domestic rabbit.

Hypofractionated radiation therapy of a thyroid tumor in a pet raccoon (Procyon lotor).

Thyroid neoplasia has been documented in raccoons; however, successful management and treatment has not been well-described. A 15-year-old, intact female pet raccoon (Procyon lotor) was examined for evaluation of a right-sided ventral cervical mass and a cough of 4 to 5 mo duration. Cytology and computed tomography (CT) findings of the mass were most consistent with a thyroid tumor. The raccoon was treated with a hypofractionated external beam radiation protocol (8 Gy/fraction for 4 once/wk fractions). Treatments were well-tolerated and no radiation-induced side effects were detected. This is the first report of radiation treatment of thyroid neoplasia in a raccoon, presenting the challenges of animals that are difficult to handle or medicate.

Radiothérapie hypofractionnée d'une tumeur thyroïdienne chez un raton-laveur ( Procyon lotor ). La néoplasie thyroïdienne a été documentée chez les ratons-laveurs; cependant, la gestion et le traitement réussis n'ont pas été bien décrits. Un raton-laveur femelle intact de 15 ans (Procyon lotor) a été examiné pour l'évaluation d'une masse cervicale ventrale droite et d'une toux d'une durée de 4 à 5 mois. Les résultats de la cytologie et de la tomodensitométrie (CT) de la masse étaient les plus compatibles avec une tumeur thyroïdienne. Le raton-laveur a été traité avec un protocole de rayonnement externe hypofractionné (8 Gy/fraction pour quatre fractions 1 fois/semaine). Les traitements ont été bien tolérés et aucun effet secondaire radio-induit n'a été détecté. Il s'agit du premier rapport de radiothérapie d'une néoplasie thyroïdienne chez un raton-laveur, présentant les défis des animaux difficiles à manipuler ou à soigner.(Traduit par Dr Serge Messier).

A three-portal laparoscopic hysterectomy in a chimpanzee (Pan troglodytes) with a uterine manipulator and vessel sealing device.

OBJECTIVE: To report the treatment and outcome of a a captive chimpanzee (Pan troglodytes) undergoing 3-portal laparoscopic hysterectomy. Additionally, the technique used for successful urinary catheterization is described. ANIMALS: A 29-year-old female intact chimpanzee with uterine bleeding. STUDY DESIGN: Clinical case report. METHODS: Uterine changes consistent with adenomyosis and/or endometriosis were noted on abdominal ultrasonographic and computed tomographic examinations. A urinary catheter was placed before a 3-portal laparoscopic hysterectomy with a uterine manipulator (VCare) and a vessel sealer (Ligasure). The uterus was submitted for histopathology. RESULTS: Preoperative urinary catheterization was achieved with several modifications and prevented bladder protrusion into the surgical field. Laparoscopy provided excellent visualization of the pelvic structures and VCare effectively maneuvered the uterus for a safe and efficient dissection. The use of the vessel sealer was effective, and bleeding was minimal. Anesthesia and surgery lasted 240 and 150 minutes, respectively. No complications were encountered. Histopathological changes of the uterus were consistent with adenomyosis and myometrial hyperplasia. The chimpanzee recovered uneventfully and returned to normal behavior with no recurrence of uterine bleeding 5 months after surgery. CONCLUSION: The 3-portal laparoscopic technique reported here allowed hysterectomy without complication in this chimpanzee. Urinary catheterization was technically challenging but successful.

Clinical presentation and treatment of lymphoma in companion rats (Rattus norvegicus; 2008-2020).

OBJECTIVE: To describe the clinical presentation, treatment, and treatment outcomes for companion rats (Rattus norvegicus) diagnosed with lymphoma. ANIMALS: All rats that presented to the exotics service and underwent postmortem examination during the time period of 2008 through 2020 were evaluated. PROCEDURES: The medical records of 35 rats were evaluated for an ante- or postmortem diagnosis of lymphoma. Cases with a diagnosis of lymphoma were further reviewed for signalment, presenting complaint, clinical signs observed on physical exam, diagnostic testing performed, and treatments administered. Postmortem gross and histologic findings were reviewed. RESULTS: 7 out of 35 rats were diagnosed with lymphoma, either ante-mortem or postmortem. The most common presenting complaint that was present in all rats with lymphoma was respiratory abnormalities. Five out of 7 rats had radiographs performed, all of which had abnormalities noted in the thoracic cavity including pulmonary nodules, cranial mediastinal widening, or alteration to the cardiac silhouette. Diagnosis via cytologic aspirates was performed in 2 cases and each was diagnostic for lymphoma; however, even with treatment, survival time following initiation of chemotherapy was short (less than or equal to 24 days). The definitive diagnosis in the remainder of the cases was via necropsy. CLINICAL RELEVANCE: Results suggest that lymphoma is a common neoplastic disease in rats and a thorough diagnostic work-up is indicated in any rat that presents for general malaise or respiratory signs.

Clinicopathologic findings and urolith composition for green iguanas (Iguana iguana) with urolithiasis: 21 cases and 132 stones (1996-2020).

OBJECTIVE: To document the clinical signs, diagnosis, and treatment of urolithiasis in green iguanas (Iguana iguana) and to report on the composition of uroliths from green iguanas submitted to the Minnesota Urolith Center for analysis. ANIMALS: 21 green iguanas with urolithiasis. PROCEDURES: Medical record databases of multiple veterinary teaching hospitals were searched from 1996 through 2020. Emails were sent to all facilities that submitted a urolith from a green iguana to the Minnesota Urolith Center from 1996 through 2020. Signalment; presenting complaint; physical examination findings; hematologic, biochemical, and diagnostic imaging findings; treatment; necropsy results; and survival times were described for each patient. RESULTS: Iguanas most commonly presented with nonspecific clinical signs, but 9 of the 21 iguanas had clinical signs associated with the urogenital tract. Twelve iguanas had a palpable mass in the caudal coelom. All uroliths were visible on radiographs. Surgery was performed on 15 iguanas; 3 died secondary to intra- or postoperative complications. Iguanas that underwent surgery had a median survival time of 39 months. Necropsy was performed on 5 iguanas, and urolithiasis contributed to the decision to euthanize or was the cause of death for 4. Uroliths from 132 iguanas were analyzed, and all were composed of 100% uric acid salts. CLINICAL RELEVANCE: Green iguanas with urolithiasis may not have clinical signs or physical examination findings associated with the urinary system, and hematologic and biochemical abnormalities are nonspecific. Green iguanas should be routinely examined for uroliths, and surgical treatment should be pursued.

Rabbit Sedation and Anesthesia.

With the increasing frequency of rabbits as veterinary patients, the expectation for high-quality, intensive veterinary care, and resultantly an understanding of anesthesia has been increasing. Sedation and general anesthesia are commonly required for many routine and emergency procedures in rabbits, and this results in the need for a strong awareness of anesthetic principles, knowledge of limitations of anesthesia, and maintenance of high standards of anesthesia.

Evaluation of the effects of a dexmedetomidine-midazolam-ketamine combination administered intramuscularly to captive red-footed tortoises (Chelonoidis carbonaria).

OBJECTIVE: To evaluate the effects of a dexmedetomidine-midazolam-ketamine (DMK) combination administered IM to captive red-footed tortoises (Chelonoidis carbonaria). ANIMALS: 12 healthy adult red-footed tortoises. PROCEDURES: In a prospective experimental study, DMK (0.1, 1.0, and 10 mg/kg, respectively) was administered IM as separate injections into the right antebrachium. Atipamezole (0.5 mg/kg, IM) and flumazenil (0.05 mg/kg, SC) were administered into the left antebrachium 60 minutes later. Times to the first treatment response and maximal treatment effect after DMK administration and time to recovery after reversal agent administration were recorded. Vital signs and reflexes or responses to stimuli were assessed and recorded at predetermined intervals. RESULTS: DMK treatment produced deep sedation or light anesthesia for ≥ 20 minutes in all tortoises. Induction and recovery were rapid, with no complications noted. Median times to first response, maximum effect, and recovery were 4.5, 35, and 14.5 minutes, respectively. Two tortoises required additional reversal agent administration but recovered < 20 minutes after the repeated injections. Mean heart and respiratory rates decreased significantly over time. All animals lost muscle tone in the neck and limbs from 35 to 55 minutes after DMK injection, but other variables including palpebral reflexes, responses to mild noxious stimuli (eg, toe pinching, tail pinching, and saline ([0.9 NaCl] solution injection), and ability to intubate were inconsistent. CONCLUSIONS AND CLINICAL RELEVANCE: DMK administration produced deep sedation or light anesthesia with no adverse effects in healthy adult red-footed tortoises. At the doses administered, deep surgical anesthesia was not consistently achieved. Anesthetic depth must be carefully evaluated before performing painful procedures in red-footed tortoises with this DMK protocol.